Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;238(2):329-340.
doi: 10.1007/s00213-020-05716-4. Epub 2021 Jan 7.

Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review

Beatriz Oda Plasencia-García  1 , Gonzalo Rodríguez-Menéndez  1 , María Isabel Rico-Rangel  1 , Ana Rubio-García  1 , Jaime Torelló-Iserte  2 , Benedicto Crespo-Facorro  3
Affiliations

Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review

Beatriz Oda Plasencia-García et al. Psychopharmacology (Berl). 2021 Feb.

Abstract

Rationale: Management of anxiety, delirium, and agitation cannot be neglected in coronavirus disease (COVID-19). Antipsychotics are usually used for the pharmacological management of delirium, and confusion and behavioral disturbances. The concurrent use of treatments for COVID-19 and antipsychotics should consider eventual drug-drug interactions OBJECTIVE: To systematically review evidence-based available on drug-drug interactions between COVID-19 treatments and antipsychotics.

Evidence review: Three databases were consulted: Lexicomp® Drug Interactions, Micromedex® Solutions Drugs Interactions, and Liverpool© Drug Interaction Group for COVID-19 therapies. To acquire more information on QT prolongation and Torsade de Pointes (TdP), the CredibleMeds® QTDrugs List was searched. The authors made a recommendation agreed to by consensus. Additionally, a systematic review of drug-drug interactions between antipsychotics and COVID-19 treatment was conducted.

Results: The main interactions between COVID-19 drugs and antipsychotics are the risk of QT-prolongation and TdP, and cytochromes P450 interactions. Remdesivir, baricinitib, and anakinra can be used concomitantly with antipsychotics without risk of drug-drug interaction (except for hematological risk with clozapine and baricinitib). Favipiravir only needs caution with chlorpromazine and quetiapine. Tocilizumab is rather safe to use in combination with antipsychotics. The most demanding COVID-19 treatments for coadministration with antipsychotics are chloroquine, hydroxychloroquine, azithromycin, and lopinavir/ritonavir because of the risk of QT prolongation and TdP and cytochromes interactions. The systematic review provides highly probable drug interaction between lopinavir/ritonavir plus quetiapine and ritonavir/indinavir plus risperidone.

Conclusions: Clinicians prescribing antipsychotics should be aware of the likely risk of drug-drug interaction with COVID-19 medication and may benefit from taking into account present recommendations of use to preserve patient safety.

Keywords: COVID-19; Drug-drug interaction; Psychopharmacotherapy; Side effects.

PubMed Disclaimer

Conflict of interest statement

Plasencia-García B.O. has received honoraria for consulting/advisory boards from Otsuka Pharmaceuticals, Lundbeck, and Janssen Johnson & Johnson and lecture honoraria from Otsuka Pharmaceuticals, Lundbeck, Janssen Johnson & Johnson, Angelini, and Pfizer. Crespo-Facorro B. has received honoraria for consulting/advisory boards from Otsuka Pharmaceuticals, Takeda, and Angelini and lecture honoraria from Janssen Johnson & Johnson, Lundbeck, Roche, and Otsuka Pharmaceutical. The other authors declare that they have no known conflicts of interest. No pharmaceutical industry or institutional sponsors participated in the study design, data collection, analysis, and interpretation of the results

References

    1. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc. 2004;44(2):136–141. doi: 10.1331/154434504773062582. - DOI - PubMed
    1. Acciavatti T, Martinotti G, Corbo M, Cinosi E, Lupi M, Ricci F, Di Scala R, D’Ugo E, De Francesco V, De Caterina R, di Giannantonio M. Psychotropic drugs and ventricular repolarisation: the effects on QT interval, T-peak to T-end interval and QT dispersion. J Psychopharmacol. 2017;31(4):453–460. doi: 10.1177/0269881116684337. - DOI - PubMed
    1. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35(9):1687–1693. doi: 10.1124/dmd.107.015511. - DOI - PMC - PubMed
    1. Aung GL, O’Brien JG, Tien PG, Kawamoto LS. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother. 2010;44(11):1850–1854. doi: 10.1345/aph.1P139. - DOI - PubMed
    1. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mourão MPG, Brito-Sousa JD, Baía-da-Silva D, Guerra MVF, Hajjar LA, Pinto RC, Balieiro AAS, Pacheco AGF, Santos JDO, Naveca FG, Xavier MS, Siqueira AM, Schwarzbold A, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857. - DOI - PubMed

Publication types

MeSH terms